MX2024012034A - Ácidos nucleicos antisentido para usarse en el tratamiento de portadores de mutaciones lmna - Google Patents
Ácidos nucleicos antisentido para usarse en el tratamiento de portadores de mutaciones lmnaInfo
- Publication number
- MX2024012034A MX2024012034A MX2024012034A MX2024012034A MX2024012034A MX 2024012034 A MX2024012034 A MX 2024012034A MX 2024012034 A MX2024012034 A MX 2024012034A MX 2024012034 A MX2024012034 A MX 2024012034A MX 2024012034 A MX2024012034 A MX 2024012034A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- antisense nucleic
- nucleic acids
- mutation carriers
- lmna mutation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22165710 | 2022-03-30 | ||
| PCT/NL2023/050168 WO2023191631A1 (en) | 2022-03-30 | 2023-03-30 | Antisense nucleic acids for use in the treatment for lmna mutation carriers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024012034A true MX2024012034A (es) | 2025-03-07 |
Family
ID=81074125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024012034A MX2024012034A (es) | 2022-03-30 | 2024-09-27 | Ácidos nucleicos antisentido para usarse en el tratamiento de portadores de mutaciones lmna |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20260002152A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4499826A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025513932A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250021303A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119790153A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023246365A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3246987A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024012034A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023191631A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025096498A1 (en) * | 2023-10-30 | 2025-05-08 | Research Institute At Nationwide Children's Hospital | Compositions and methods for treating diseases or conditions associated with progerin expression |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003070918A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| US8258109B2 (en) * | 2005-10-20 | 2012-09-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of LMNA expression |
| WO2020061497A1 (en) * | 2018-09-20 | 2020-03-26 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation of lmna expression |
-
2023
- 2023-03-30 US US18/851,915 patent/US20260002152A1/en active Pending
- 2023-03-30 AU AU2023246365A patent/AU2023246365A1/en active Pending
- 2023-03-30 CA CA3246987A patent/CA3246987A1/en active Pending
- 2023-03-30 KR KR1020247036183A patent/KR20250021303A/ko active Pending
- 2023-03-30 JP JP2025504030A patent/JP2025513932A/ja active Pending
- 2023-03-30 CN CN202380041546.9A patent/CN119790153A/zh active Pending
- 2023-03-30 EP EP23714866.3A patent/EP4499826A1/en active Pending
- 2023-03-30 WO PCT/NL2023/050168 patent/WO2023191631A1/en not_active Ceased
-
2024
- 2024-09-27 MX MX2024012034A patent/MX2024012034A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023191631A1 (en) | 2023-10-05 |
| EP4499826A1 (en) | 2025-02-05 |
| KR20250021303A (ko) | 2025-02-12 |
| JP2025513932A (ja) | 2025-04-30 |
| CA3246987A1 (en) | 2023-10-05 |
| CN119790153A (zh) | 2025-04-08 |
| US20260002152A1 (en) | 2026-01-01 |
| AU2023246365A1 (en) | 2024-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Niehrs et al. | Regulatory R-loops as facilitators of gene expression and genome stability | |
| US10760081B2 (en) | Compositions and methods for enhancing CRISPR activity by POLQ inhibition | |
| Duechler et al. | Nucleoside modifications in the regulation of gene expression: focus on tRNA | |
| Chen et al. | Preferential production of RNA rings by T4 RNA ligase 2 without any splint through rational design of precursor strand | |
| IN2014CN04590A (cg-RX-API-DMAC7.html) | ||
| Yan et al. | MicroRNA‐22 promoted osteogenic differentiation of human periodontal ligament stem cells by targeting HDAC6 | |
| AU2019252204A2 (en) | Novel small activating RNA | |
| EP2046970B2 (en) | A method of producing recombinant biological products | |
| CN106032532A (zh) | 一种小激活rna及其制备方法和应用 | |
| BRPI0413542A (pt) | molécula isolada de polinucleotìdeo, polipeptìdeo, molécula de dna recombinante, vetor de expressão, organismo recombinante, bem como processos para produção de ácido l-ascórbico, de l-sorbosona desidrogenase e de vitamina c | |
| US9834768B2 (en) | Effective method for specific gene silencing using artificial small RNA | |
| Klanert et al. | Endogenous microRNA clusters outperform chimeric sequence clusters in Chinese hamster ovary cells | |
| Pereira et al. | Affinity approaches in RNAi-based therapeutics purification | |
| Morlon et al. | The complete nucleotide sequence of the colicinogenic plasmid ColA. High extent of homology with ColE1 | |
| JP2016532445A (ja) | 組換えタンパク質の生産のための哺乳動物生産細胞の生成のための手段及び方法 | |
| Murina et al. | Bacterial small regulatory RNAs and Hfq protein | |
| US9970004B2 (en) | Nucleic acid molecule, expression cassette, expression vector, eukaryotic host cell, induction method of RNA interferencde in eukaryotic host and use of the nucleic acid molecule in therapy of diseases induced by expansion of trinucleotide CAG repeats | |
| Bobrowicz et al. | Polyadenylation and degradation of mRNA in mammalian mitochondria: a missing link? | |
| Stiefel et al. | Noncoding RNAs, post-transcriptional RNA operons and Chinese hamster ovary cells | |
| US20240101983A1 (en) | Programmable rna editing platform | |
| MX2021013361A (es) | Molecula oligomerica de acido nucleico y uso de esta en el tratamiento de la porfiria aguda intermitente. | |
| WO2022266486A3 (en) | Products and compositions | |
| Gott et al. | Insertion/deletion editing in Physarum polycephalum | |
| CN119790153A (zh) | 用于lmna突变携带者治疗的反义核酸 | |
| MX2008013416A (es) | Medios para inhibir la expresion de cd31. |